| ATCC 35061| DSM 861| Methanobrevibacter smithii| Methanobrevibacter smithii Balch and Wolfe 1981| OCM 144| strain PS
Digestive processes: Methanobrevibacter smithii is involved in the digestion of dietary carbohydrates in the human gut. It consumes hydrogen produced by other microorganisms during the fermentation of complex carbohydrates and uses it to produce methane. This process helps regulate the microbial ecosystem in the gut and influences the efficiency of energy extraction from the diet.
Association with obesity: Some studies have suggested an association between the abundance of Methanobrevibacter smithii in the gut microbiota and obesity. Methane production by Methanobrevibacter smithii may influence energy metabolism and contribute to increased energy harvest from the diet. However, the exact mechanisms underlying this association and whether Methanobrevibacter smithii directly contributes to obesity or is simply a marker of dysbiosis are still under investigation.
Inflammatory bowel disease (IBD): Methanobrevibacter smithii has been detected in the gut microbiota of individuals with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. However, its role in the pathogenesis of IBD is not fully understood. Some studies have suggested that methane production by Methanobrevibacter smithii may have anti-inflammatory effects in the gut, while others have proposed that it may exacerbate intestinal inflammation by altering microbial interactions.
Hydrogen disposal: Methanobrevibacter smithii plays a role in hydrogen disposal in the gut by consuming hydrogen produced during microbial fermentation. In conditions where excess hydrogen accumulates in the gut, such as small intestinal bacterial overgrowth (SIBO), methane production by Methanobrevibacter smithii may help alleviate symptoms associated with hydrogen accumulation, such as bloating and abdominal discomfort.
Potential therapeutic target: Given its abundance and potential role in gut health and disease, Methanobrevibacter smithii has been proposed as a potential therapeutic target for modulating the gut microbiota. Strategies aimed at selectively targeting Methanobrevibacter smithii, such as antimicrobial treatments or dietary interventions, are being investigated for their potential to modulate methane production and improve gastrointestinal health.
A lot more information is available when you are logged in and raise the display level
Other Sources for more information:
Statistics | NCBI | Data Punk | End Products Produced |
Different labs use different software to read the sample. See this post for more details.
One lab may say you have none, another may say you have a lot! - This may be solely due to the software they are using to estimate.
We deem lab specific values using values from the KM method for each specific lab to be the most reliable.
Lab | Frequency | UD-Low | UD-High | KM Low | KM High | Lab Low | Lab High | Mean | Median | Standard Deviation | Box Plot Low | Box Plot High | KM Percentile Low | KM Percentile High |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Other Labs | 1.15 | 5 | 477000 | 0 | 207168 | 26183 | 7000 | 92339.1 | 0 | 27911 | 0 %ile | 100 %ile | ||
biomesight | 22.42 | 0 | 20 | 10 | 9990 | 0 | 10419 | 1372.2 | 300 | 4615.6 | 0 | 1800 | 0 %ile | 97.9 %ile |
thryve | 19.49 | 0 | 15 | 1 | 5393 | 0 | 16984 | 3418.6 | 696 | 6921.2 | 0 | 5204 | 0 %ile | 92 %ile |
ubiome | 26.36 | 0 | 361 | 21 | 86128 | 0 | 41124 | 11576.9 | 5460 | 15075.3 | 0 | 25231 | 0 %ile | 100 %ile |
Source of Ranges | Low Boundary | High Boundary | Low Boundary %age | High Boundary %age |
---|---|---|---|---|
Thorne (20/80%ile) | 0 | 190.4 | 0 | 0.019 |
Medivere | 0 | 300 | 0 | 0.03 |
XenoGene | 0 | 700 | 0 | 0.07 |
Lab | Frequency Seen | Average | Standard Deviation | Sample Count | Lab Samples |
---|---|---|---|---|---|
BiomeSight | 23.194 % | 0.121 % | 0.414 % | 687.0 | 2962 |
bugspeak | 100 % | 0.007 % | % | 1.0 | 1 |
CerbaLab | 66.667 % | 0.001 % | 0 % | 2.0 | 3 |
CosmosId | 9.375 % | 0.468 % | 0.407 % | 3.0 | 32 |
custom | 40.984 % | 1.541 % | 0.476 % | 25.0 | 61 |
es-xenogene | 48.276 % | 4.092 % | 12.572 % | 14.0 | 29 |
GanzimmunDiag | 100 % | 0.015 % | 0 % | 3.0 | 3 |
Microba | 14.286 % | 1.472 % | 0.768 % | 4.0 | 28 |
Microba1 | 100 % | 2.67 % | % | 1.0 | 1 |
SequentiaBiotech | 5.556 % | 0.664 % | 0.551 % | 2.0 | 36 |
Thorne | 7.921 % | 0.181 % | 0.273 % | 8.0 | 101 |
Thryve | 19.582 % | 0.307 % | 0.662 % | 272.0 | 1389 |
uBiome | 26.389 % | 1.169 % | 1.513 % | 209.0 | 792 |
|
And display level must be raised above public.
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.